These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [A remarkable effect of K-18 (IgG-melphalan complex) in a case of RAEB with hypoplastic marrow].
    Author: Fujikawa K, Mogi Y, Ito K, Tsushima N, Saito T, Ishigaki S, Watanabe N, Kohgo Y, Mikami T, Niitsu Y.
    Journal: Gan To Kagaku Ryoho; 1991 Feb; 18(2):287-91. PubMed ID: 1992922.
    Abstract:
    A 63-year-old male with refractory anemia with excess of blasts (RAEB) and hypoplastic marrow was treated with K-18 (240 mg/day P.O.). On admission, peripheral blood revealed pancytopenia. Bone marrow specimen revealed severe hypocellularity with 18.9% of the blast cells. Ten months later, the blast cells in the bone marrow decreased to 3.8%, and complete remission (CR) was obtained. CR was eight weeks. Duration of response (CR + PR) continued for about eight months. K-18 is an antitumor agent with minimal side effects, and seems to be effective for RAEB with hypoplastic marrow.
    [Abstract] [Full Text] [Related] [New Search]